Life-extending lung cancer treatment, Vizimpro recommended on NHS as a first-line treatment for non-small-cell lung cancer

Vizimpro recommended on NHS for NSCLC – NICE

Life-extending lung cancer treatment, Vizimpro recommended on NHS as a first-line treatment for non-small-cell lung cancer. Dacomitinib (Vizimpro, Pfizer) has been recommended as a first-line...
LEO Pharma colleagues will undertake charity walk for National Eczema Society

LEO Pharma takes walk in aid of National Eczema Society

27 colleagues from LEO Pharma are taking on the challenge of walking a marathon (26.2 miles) along the Thames Path, from Henley to Windsor,...
Cemiplimab recommended in Cancer Drugs Fund

Cemiplimab recommended in Cancer Drugs Fund

Cemiplimab recommended in the Cancer Drugs Fund following draft guidance from the National Institute for Health and Care Excellence (NICE). NICE has issued draft guidance...
treatment to slow Parkinson's

Parkinson’s UK invests £1m to find treatment to slow Parkinson’s

Parkinson’s UK have partnered with NRG Therapeutics to find a treatment to slow Parkinson’s. Charity Parkinson’s UK will invest up to £1m in NRG Therapeutics...
Patients Know Best and HealthUnlocked sign partnership agreement to improve social wellbeing for patients.

Chiesi’s Procysbi ® approved for use in Ireland for patients with nephropathic cystinosis

Chiesi Limited has announced that Procysbi (mercaptamine bitartrate gastro-resistant hard capsules) has been approved for use, in patients with proven nephropathic cystinosis, by the...

Janssen receives positive CHMP opinion for Imbruvica®▼

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...
Pharma invests £377m in UK R&D

Pharma invests £377m in UK R&D collaborations

New figures published by the ABPI show that pharma invests £377m in UK R&D collaborations, working with healthcare professionals and organisations to improve care...
BMA writes to NHS Property service over rise in service fees for GP practices

BMA warns NHS Property Services over ‘astronomical’ fee rise

The BMA has written to NHS Property Services (NHSPS) asking it to urgently respond to concerns over the worrying rise in service fees faced...

AbbVie to acquire Allergan in “transformative move”

Abbvie to acquire Allergan after entering into a definitive transaction agreement under which AbbVie will acquire the company in a cash and stock transaction...
and the Wellcome Sanger Institute

Superbug MRSA susceptible to existing antibiotics

New MRC funded research from scientists at the University of Cambridge and the Wellcome Sanger Institute finds superbug MRSA susceptible to existing antibiotics. Methicillin-resistant Staphylococcus aureus (MRSA)...

Latest articles

Oral health has been isolated from traditional healthcare and health policy for too long fuelling an oral health crisis according to a Lancet Series.

Big Sugar and neglect by global health community fuel oral health crisis 

Oral health has been isolated from traditional healthcare and health policy for too long, despite the major global public health burden of oral diseases,...
New statistics show decrease in animals used for R&D

New statistics show decrease in animals used for R&D

The Home Office has released its annual statistics on animals used in research in Great Britain. It shows 3.52 million procedures were carried out...
New insight into microRNA function has been published by scientists at the University of Eastern Finland and the University of Oxford.

New insight into microRNA function can give gene therapy a boost

New insight into microRNA function has been published by scientists at the University of Eastern Finland and the University of Oxford. They have shown that...

Popular articles

pain relief patch released by nurofen

Nurofen launches a 24 hour ibuprofen pain relief patch

Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen.  Despite body pain being among the most commonly...
NICE has approved a first-in-class gene silencing therapy for hereditary amyloidosis.

Gene silencing therapy for hereditary amyloidosis approved by NICE

NICE has approved a first-in-class gene silencing therapy for hereditary amyloidosis. RNA interference (RNAi) therapeutics company, Alnylam UK Limited has welcomed a decision from the...
AstraZeneca to appeal NICE's osimertinib decision

AstraZeneca to appeal NICE’s osimertinib decision

AstraZeneca to appeal NICE's osimertinib decision following it not being recommended for use within NHS England. AstraZeneca will appeal a decision by the National Institute...

Top 5 R&D hubs in the UK

Read this cover story in the June issue of Pf Magazine here.    Join us on a tour of inspirational research and development centres. ...

How to write a standout CV

The job market is getting more competitive by the day, as highly-qualified candidates fiercely compete for the top jobs. A carefully constructed CV is...